CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Most-followed names in the same sector.
Additional public equities from our tracked universe.
Large-cap symbols investors frequently compare.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Our full report includes a DCF valuation model, 5-year financial analysis, competitive moat assessment, risk factors, and a clear BUY / HOLD / SELL recommendation — the same analysis hedge funds pay thousands for.